Washington, DC – George Vradenburg, Chairman and Co-founder of USAgainstAlzheimer’s, today praised Dr. Margaret Hamburg, who announced that she is stepping down as the Commissioner of the Food and Drug Administration (FDA) in March.

“We in the Alzheimer’s community are grateful to Commissioner Hamburg for her efforts to enhance innovation and expedite the drug development and review process in her tenure at the FDA.  Her very successful track record on that score is well known and speaks for itself,”
George Vradenburg said.  “In particular, we appreciate her forward-leaning positions regarding the assessment and review of potential Alzheimer’s treatments.  We urge the FDA to continue to embrace novel endpoints and innovative cognitive assessment tools useful for the prevention of Alzheimer’s and other dementias in the months and years ahead.”

###

USAgainstAlzheimer’s is an entrepreneurial and innovative organization demanding a life-cycle solution to Alzheimer's.  Driven by the suffering of millions of families, USAgainstAlzheimer’s presses for greater urgency and collaboration from government, industry and the scientific community in the quest for an Alzheimer's cure – accomplishing this through effective leadership, collaborative advocacy, and strategic investments. 

Founded in 2010, USAgainstAlzheimer’s has worked across sectors to: (1) secure the national goal of preventing and effectively treating Alzheimer’s by 2025 and helping secure more than $360 million in additional public funding for Alzheimer’s research over the past few years; (2) drive global efforts that resulted in the leaders of the world’s most powerful nations, the G7 group, to embrace a similar 2025 goal and to call for greater levels of research investment and collaboration; and (3) forge industry commitments to improve efficiencies for an expedited drug discovery and approval process.